Are you living with MBC? Take an anonymous survey about your thoughts on clinical trials – even if you’ve never participated in one – to help improve access and representation in metastatic breast cancer research.
Each month, our Here All Year campaign explores a new topic around metastatic breast cancer—from myth and stigma busters, to new research and strategies for improving outcomes. Want to help make a difference for people living with MBC, all year long? Dig deeper into the research, explore the available resources and share them on your social and email channels.
The featured topic for July is Metastatic Lobular Breast Cancer.
MBC Connect 2.0 is an interactive, web and mobile-friendly, patient experience registry where you can share information about your MBC disease history, experiences, and quality of life – and now, get potential matches to clinical trials. Join today, or update your app to access the latest features.
NEW YORK, Oct. 23, 2019 /PRNewswire/ — A retrospective analysis – reported in the journal Cancer by Judith Malmgren, PhD, and co-authors – studied patients in the Surveillance, Epidemiology, and End Results (SEER) 9 population and an institutional cohort with de novo metastatic breast cancer (MBC), which is a first diagnosis of breast cancer that is stage IV. The SEER 9 population includes cancer patients in nine US regions including Seattle-Puget Sound, and is representative of the US population. The institutional cohort includes patients with breast cancer who are followed over time, who live in the Seattle-Puget Sound registry area, and whose cases are included in SEER Seattle-Puget Sound. Approximately 13,000 new cases of de novo MBC are diagnosed annually in the United States.
